Fenofibratum [Inn-Latin]
Brand names,
Fenofibratum [Inn-Latin]
Analogs
Fenofibratum [Inn-Latin]
Brand Names Mixture
Fenofibratum [Inn-Latin]
Chemical_Formula
C20H21ClO4
Fenofibratum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic3/fenofibrate.htm
Fenofibratum [Inn-Latin]
fda sheet
Fenofibratum [Inn-Latin]
msds (material safety sheet)
Fenofibratum [Inn-Latin]
Synthesis Reference
No information avaliable
Fenofibratum [Inn-Latin]
Molecular Weight
360.831 g/mol
Fenofibratum [Inn-Latin]
Melting Point
80.5 °C
Fenofibratum [Inn-Latin]
H2O Solubility
0.25mg/ml at 25 °C
Fenofibratum [Inn-Latin]
State
Solid
Fenofibratum [Inn-Latin]
LogP
5.575
Fenofibratum [Inn-Latin]
Dosage Forms
Capsule; Tablet
Fenofibratum [Inn-Latin]
Indication
For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Fenofibratum [Inn-Latin]
Pharmacology
Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.
Fenofibratum [Inn-Latin]
Absorption
Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Fenofibratum [Inn-Latin]
side effects and Toxicity
LD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.
Fenofibratum [Inn-Latin]
Patient Information
No information avaliable
Fenofibratum [Inn-Latin]
Organisms Affected
Humans and other mammals